The KLHL7 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KLHL7 gene in a human lung adenocarcinoma background. The polyclonal format preserves genetic diversity while ensuring effective gene silencing, making it suitable for pooled screening and bulk analysis in cellular assays without clonal artifacts. This heterogeneous pool of cells harbors loss-of-function modifications, enabling robust functional studies that capture population-level responses. The polyclonal nature mitigates clonal variability, ensuring representative phenotypic outcomes in functional genomics studies.
The NCI-H1975 parental cell line is a widely used model of non-small cell lung cancer (NSCLC), established from a female patient with advanced lung adenocarcinoma. These epithelial cells harbor activating EGFR mutations (L858R and T790M), the latter conferring resistance to first-generation tyrosine kinase inhibitors. This model is instrumental for elucidating mechanisms of acquired resistance and for screening novel compounds that overcome T790M-mediated resistance, making it a cornerstone in NSCLC research.
KLHL7 functions as a substrate adaptor for the Cullin3-RING E3 ubiquitin ligase complex, composed of CUL3 and RBX1, which cooperates with E2 ubiquitin-conjugating enzymes to transfer ubiquitin onto target proteins. Through its BTB and Kelch-repeat domains, KLHL7 recruits specific substrates such as the actin-capping protein components CAPZA1 and CAPZB, promoting their K48-linked polyubiquitination and subsequent 26S proteasomal degradation. This activity regulates actin dynamics, thereby influencing cell morphology, motility, and adhesion. Dysregulation of this process is associated with retinitis pigmentosa and cancer, highlighting the biological significance of KLHL7-mediated proteolysis.
In the NCI-H1975 background, disruption of KLHL7 allows dissection of its role in lung adenocarcinoma biology, particularly given the interplay between actin cytoskeleton remodeling and oncogenic signaling. By ablating KLHL7-mediated proteolysis of actin-capping proteins, researchers can assess resultant changes in actin polymerization and cellular behavior. Given that NCI-H1975 cells exhibit constitutive EGFR signaling, assessing the impact of KLHL7 loss on downstream effectors and migratory properties can uncover novel therapeutic vulnerabilities. The model thus bridges ubiquitin-proteasome function and key malignant phenotypes in NSCLC.
These polyclonal knockout cells are ideal for a spectrum of experimental applications, including Western blotting to verify loss of KLHL7 expression, ubiquitination assays to examine substrate turnover, co-immunoprecipitation to map protein interaction networks, and immunofluorescence to visualize cytoskeletal alterations. Functional studies such as cell migration and proliferation assays, colony formation assays, and in vivo xenograft models further enable drug target validation and mechanistic exploration. Moreover, the cells can be employed in high-throughput screens for modulators of the ubiquitin-proteasome system and in co-culture models to study tumor-stroma interactions. For additional information, please contact Ascent Research.
